[Diphosphonate therapy and osteonecrosis of the jaw].
Løkken
Per
P
Seksjon for odontologisk farmakologi og farmakoterapi Universitetet i Oslo Postboks 1119 Blindern 0317 Oslo. perl@odont.uio.no.
Skoglund
Lasse A
LA
Skjelbred
Per
P
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003729:Dental Care; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D010024:Osteoporosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010353:Patient Education as Topic; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019386:Alendronate